Quark Pharmaceuticals and Major Pharmaceutical Company Enter into Licensing Option Agreement for the p53 Suppressor Drug QPI-1002, the First siRNA Administered Systemically in Human

7/15/2010

Nitto Denko and Quark Pharmaceuticals to Enter into Collaboration to Develop a Novel siRNA Anti-fibrotic Drug

6/28/2010

Quark Pharmaceutical’s QPI-1007 Exhibits Neuroprotective Effects in Glaucoma Model

6/24/2010

Quark Pharmaceuticals Announces Presentations of its Two siRNA Drug Candidates at Glaucoma & Retinopathies 2010

6/15/2010

Quark Granted European Orphan Drug Status for QPI-1002 for the Prophylaxis of Delayed Graft Function in Kidney Transplant Patients

6/10/2010

Quark Pharmaceuticals Closes $10 Million Financing

SBI Holdings, Inc. CEO Yoshitaka Kitao Appointed to Board. Funds to Support Advancing Clinical Pipeline.

5/17/2010

Quark Pharmaceuticals Announces Nature Medicine Publication for Role of RTP801 in Pulmonary Injury and Emphysema

5/6/2010

Quark Pharmaceuticals Development Partner Pfizer Presents In Vivo Activity of PF-04523655 at ARVO

5/4/2010

Quark to Present Data on Predicting Risk of Delayed Graft Function in Kidney Transplant Patients at American Transplant Congress

5/4/2010

Quark to Present Phase I Data for QPI-1002 in DGF

3/1/2010

Quark Announces Dosing of the First Patient in Phase I Clinical Trial of its Ocular Neuroprotective Agent, QPI-1007

2/16/2010

FDA Grants Orphan Drug Status for Quark’s QPI-1002 for the Prophylaxis of Delayed Graft Function in Kidney Transplant Patients